Moleculin Biotech agreed to work together with Norway-based University of Bergen to advance research of Moleculin's WP1066 for patients with glioblastoma and melanoma. A clinical trial of the drug candidate is expected to start by the end of this year.
Moleculin, Norwegian university partner on immune stimulation drug study
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.